Literature DB >> 28429168

Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis.

Ji-Chan Jang1,2, Yong-Gyun Jung3,4,5, Jungil Choi6, Hyunju Jung7, Sungweon Ryoo8,9.   

Abstract

This study aimed to provide information that bedaquilline is significantly effective for treatment of totally drug resistant (TDR) Mycobacterium tuberculosis that shows resistant to all first- and second-line drugs-using an innovative disc agarose channel (DAC) system. Time-lapse images of single bacterial cells under culture conditions with different concentrations of bedaquiline were analysed by image processing software to determine minimum inhibitory concentrations (MICs). Bedaquiline inhibited the growth of TDR M. tuberculosis strains, with MIC values ranging from 0.125 to 0.5 mg/L. The results of the present study demonstrate that bedaquiline, newly approved by the United States Food and Drug Administration (FDA), may offer therapeutic solutions for TDR-TB.

Entities:  

Keywords:  Mycobacterium tuberculosis; bedaquiline; totally drug resistant Mycobacterium tuberculosis

Mesh：

Substances：

Year:  2017        PMID： 28429168     DOI： 10.1007/s12275-017-6630-1

Source DB:  PubMed          Journal:  J Microbiol        ISSN： 1225-8873            Impact factor:   3.422


  20 in total

1.  Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease?

Authors:  G B Migliori; R Centis; L D'Ambrosio; A Spanevello; E Borroni; D M Cirillo; G Sotgiu
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

2.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

Authors:  Andreas H Diacon; Alexander Pym; Martin Grobusch; Ramonde Patientia; Roxana Rustomjee; Liesl Page-Shipp; Christoffel Pistorius; Rene Krause; Mampedi Bogoshi; Gavin Churchyard; Amour Venter; Jenny Allen; Juan Carlos Palomino; Tine De Marez; Rolf P G van Heeswijk; Nacer Lounis; Paul Meyvisch; Johan Verbeeck; Wim Parys; Karel de Beule; Koen Andries; David F Mc Neeley
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

3.  Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis.

Authors:  Shashank Gupta; Keira A Cohen; Kathryn Winglee; Mamoudou Maiga; Bassirou Diarra; William R Bishai
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

4.  Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system.

Authors:  Gabriela Torrea; Nele Coeck; Christel Desmaretz; Tim Van De Parre; Tijs Van Poucke; Nacer Lounis; Bouke C de Jong; Leen Rigouts
Journal:  J Antimicrob Chemother       Date:  2015-05-14       Impact factor: 5.790

5.  A rapid antimicrobial susceptibility test based on single-cell morphological analysis.

Authors:  Jungil Choi; Jungheon Yoo; Mincheol Lee; Eun-Geun Kim; Ji Soo Lee; Seungok Lee; Seik Joo; Sang Hoon Song; Eui-Chong Kim; Jung Chan Lee; Hee Chan Kim; Yong-Gyun Jung; Sunghoon Kwon
Journal:  Sci Transl Med       Date:  2014-12-17       Impact factor: 17.956

6.  Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan.

Authors:  Jung-Yien Chien; Chih-Cheng Lai; Che-Kim Tan; Shun-Tien Chien; Chong-Jen Yu; Po-Ren Hsueh
Journal:  J Antimicrob Chemother       Date:  2013-04-10       Impact factor: 5.790

Review 7.  Totally drug-resistant tuberculosis and adjunct therapies.

Authors:  S K Parida; R Axelsson-Robertson; M V Rao; N Singh; I Master; A Lutckii; S Keshavjee; J Andersson; A Zumla; M Maeurer
Journal:  J Intern Med       Date:  2014-06-18       Impact factor: 8.989

8.  Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method.

Authors:  Anandi Martin; Mirtha Camacho; Françoise Portaels; Juan Carlos Palomino
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

9.  OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.

Authors:  Makoto Matsumoto; Hiroyuki Hashizume; Tatsuo Tomishige; Masanori Kawasaki; Hidetsugu Tsubouchi; Hirofumi Sasaki; Yoshihiko Shimokawa; Makoto Komatsu
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

10.  Bedaquiline: First FDA-approved tuberculosis drug in 40 years.

Authors:  Rajiv Mahajan
Journal:  Int J Appl Basic Med Res       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.